Clinical Trials Logo

Refractory Neoplasm clinical trials

View clinical trials related to Refractory Neoplasm.

Filter by:
  • None
  • Page 1

NCT ID: NCT04239092 Recruiting - Neuroblastoma Clinical Trials

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Start date: June 5, 2020
Phase: Phase 1
Study type: Interventional

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

NCT ID: NCT03678883 Active, not recruiting - Cancer Clinical Trials

9-ING-41 in Patients With Advanced Cancers

Start date: January 4, 2019
Phase: Phase 2
Study type: Interventional

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

NCT ID: NCT03017833 Completed - Clinical trials for Advanced Malignant Solid Neoplasm

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

Start date: March 12, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of sapanisertib and metformin in treating patients with cancers that have spread to other parts of the body (advanced/metastatic), have come back (recurrent), or do not respond to treatment (refractory). Sapanisertib and metformin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.